Skip to content
Wild Insight

Individuals Coming Off Anti-Obesity Jabs Put On Weight at a Quadrupled Rate Compared to Those on Conventional Diets

Image of pharmaceutical syringe and weighing machine
Weight management often requires long-term strategies.

A recent study suggests that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.

Published data in a major health publication shows that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month after stopping.

"People using such medications need to be informed of the potential of fast weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.

This pace of recovery means a reversion to pre-treatment weight in about 18 months.

Weighing Approaches

The analysis, which looked at dozens of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.

Researchers emphasize that people who lose weight through lifestyle changes alone generally experience a more gradual weight regain—perhaps 100 grams monthly—once they finish.

Explaining the Rapid Rebound

Doctors believe the way of the injections accounts for the amplified regain.

GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.

"Sustained high doses of GLP-1 levels far above than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.

"Discontinuation of this hormone supplement means appetite is uncontrolled, making excessive eating a significant risk."

An Ongoing Disease?

The NHS advise the jabs for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.

Professionals contend that, considering the high risk of relapse, the therapy might need to be long-term.

This perspective is reinforced by pharmaceutical companies, who say that the results "highlight the chronic character of obesity," comparing it to managing conditions like high blood pressure.

User Experiences

Individuals who have stopped the jabs describe a powerful resurgence of appetite.

"It felt as if a switch flipping and I was suddenly starving," said an individual.

This challenge is worsened if individuals have not established lasting dietary or behavioural changes during treatment.

Growing Interest

Recent estimates show that millions of adults in the UK have used these injections in the last 12 months, with interest being substantial.

  • Use is higher among women than men.
  • The 40s and 50s age group shows the highest level of interest.
  • A large proportion access the drugs through private healthcare rather than the NHS.

Ultimately, experts stress that while these medications are powerful tools for weight loss, they are not a magic fix and maintained weight loss hinges on combined behavioural support.

About the author

Jeffrey Benitez

Eleanor is a wildlife biologist and nature writer with over a decade of experience in conservation.

Wild Insight

Type to search articles.